HRP20201433T1 - Supstituirani (e)-n´- (1-feniletiliden) analozi benzohidrazida kao inhibitori histonske demetilaze - Google Patents
Supstituirani (e)-n´- (1-feniletiliden) analozi benzohidrazida kao inhibitori histonske demetilaze Download PDFInfo
- Publication number
- HRP20201433T1 HRP20201433T1 HRP20201433TT HRP20201433T HRP20201433T1 HR P20201433 T1 HRP20201433 T1 HR P20201433T1 HR P20201433T T HRP20201433T T HR P20201433TT HR P20201433 T HRP20201433 T HR P20201433T HR P20201433 T1 HRP20201433 T1 HR P20201433T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- compound according
- pharmaceutically acceptable
- independently selected
- polyhaloalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523801P | 2011-08-15 | 2011-08-15 | |
| PCT/US2012/050948 WO2013025805A1 (en) | 2011-08-15 | 2012-08-15 | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
| EP12823540.5A EP2744330B1 (en) | 2011-08-15 | 2012-08-15 | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201433T1 true HRP20201433T1 (hr) | 2020-12-11 |
Family
ID=47715455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201433TT HRP20201433T1 (hr) | 2011-08-15 | 2012-08-15 | Supstituirani (e)-n´- (1-feniletiliden) analozi benzohidrazida kao inhibitori histonske demetilaze |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8987335B2 (https=) |
| EP (1) | EP2744330B1 (https=) |
| JP (1) | JP6122006B2 (https=) |
| KR (1) | KR101983537B1 (https=) |
| CN (1) | CN103929960B (https=) |
| AU (1) | AU2012296639B2 (https=) |
| BR (1) | BR112014003382B1 (https=) |
| CA (1) | CA2843609C (https=) |
| CY (1) | CY1123345T1 (https=) |
| DK (1) | DK2744330T3 (https=) |
| EA (1) | EA026389B1 (https=) |
| ES (1) | ES2821548T3 (https=) |
| HK (1) | HK1200052A1 (https=) |
| HR (1) | HRP20201433T1 (https=) |
| HU (1) | HUE050962T2 (https=) |
| IL (1) | IL230728A (https=) |
| IN (1) | IN2014CN00961A (https=) |
| LT (1) | LT2744330T (https=) |
| MX (1) | MX356486B (https=) |
| PL (1) | PL2744330T3 (https=) |
| PT (1) | PT2744330T (https=) |
| SG (1) | SG2014009609A (https=) |
| SI (1) | SI2744330T1 (https=) |
| SM (1) | SMT202000551T1 (https=) |
| WO (1) | WO2013025805A1 (https=) |
| ZA (1) | ZA201400881B (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9266838B2 (en) | 2011-08-15 | 2016-02-23 | University Of Utah Research Foundation | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors |
| RS55764B1 (sr) | 2012-10-02 | 2017-07-31 | Gilead Sciences | Inhibitori histonskih demetilaza |
| CA2901022C (en) * | 2013-02-27 | 2021-05-04 | Epitherapeutics Aps | Substituted pyridine compounds as inhibitors of histone demethylases |
| JP6320506B2 (ja) * | 2013-03-12 | 2018-05-09 | セルジーン クオンティセル リサーチ，インク． | ヒストンデメチラーゼ阻害剤 |
| NZ715331A (en) | 2013-06-19 | 2019-09-27 | The Univ Of Utah Research Foundation | Substituted (e)-n’-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
| MX373103B (es) | 2014-02-13 | 2020-04-17 | Incyte Holdings Corp | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| SI3105218T1 (sl) | 2014-02-13 | 2019-11-29 | Incyte Corp | Ciklopropilamini kot inhibitorji LSD1 |
| WO2015153516A1 (en) | 2014-04-04 | 2015-10-08 | University Of Florida Research Foundation | Hdac inhibitor compounds and methods of treatment |
| JP2017518312A (ja) * | 2014-06-05 | 2017-07-06 | ユニバーシティ・オブ・カンザス | マルメリン類似体および癌治療における使用方法 |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| SG11201701182VA (en) | 2014-08-27 | 2017-03-30 | Gilead Sciences Inc | Compounds and methods for inhibiting histone demethylases |
| EP2993175A1 (en) | 2014-09-05 | 2016-03-09 | IEO - Istituto Europeo di Oncologia Srl | Thienopyrroles as histone demethylase inhibitors |
| CN106146361A (zh) * | 2015-03-16 | 2016-11-23 | 四川大学 | 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途 |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| CA2987876A1 (en) | 2015-06-12 | 2016-12-15 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| LT3334709T (lt) | 2015-08-12 | 2025-03-10 | Incyte Holdings Corporation | Lsd1 inhibitoriaus druskos |
| ES3057783T3 (en) | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| WO2017158136A1 (en) | 2016-03-16 | 2017-09-21 | Oryzon Genomics, S.A. | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| JP6999574B2 (ja) * | 2016-04-22 | 2022-01-18 | インサイト・コーポレイション | Ｌｓｄ１阻害剤の製剤 |
| EP3246330A1 (en) | 2016-05-18 | 2017-11-22 | Istituto Europeo di Oncologia S.r.l. | Imidazoles as histone demethylase inhibitors |
| EP3487490A4 (en) * | 2016-07-19 | 2020-01-15 | The General Hospital Corporation | TARGETING COMPOUNDS OF CANCER STEM CELLS |
| WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| WO2018083138A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| US20200069677A1 (en) | 2016-12-09 | 2020-03-05 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
| CN106831489B (zh) * | 2017-03-23 | 2018-04-17 | 郑州大学 | 苯环丙胺酰腙类化合物、制备方法及其应用 |
| MX2020001323A (es) | 2017-08-03 | 2020-03-20 | Oryzon Genomics Sa | Metodos para tratar alteraciones del comportamiento. |
| ES2986559T3 (es) | 2017-08-18 | 2024-11-11 | St Europeo Di Oncologia S R L | Derivados de indol como inhibidores de la histona desmetilasa |
| WO2019068326A1 (en) | 2017-10-05 | 2019-04-11 | Université D'aix-Marseille | INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| CN109793742A (zh) * | 2019-03-04 | 2019-05-24 | 四川大学华西医院 | 一种药物化合物应用 |
| CN109758442B (zh) * | 2019-03-20 | 2021-08-17 | 武汉大学 | 二芳基酰肼类化合物在制备抗流感病毒药物中的应用 |
| ES3053813T3 (en) | 2019-03-20 | 2026-01-26 | Oryzon Genomics Sa | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
| SG11202109159VA (en) | 2019-03-20 | 2021-10-28 | Oryzon Genomics Sa | Methods of treating borderline personality disorder |
| CN114341366A (zh) | 2019-07-05 | 2022-04-12 | 奥莱松基因组股份有限公司 | 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法 |
| WO2022020804A1 (en) * | 2020-07-24 | 2022-01-27 | Salarius Pharmaceuticals Llc | Methods of inhibiting lysine-specific demethylase 1 (lsd-1) |
| EP3964204A1 (en) | 2020-09-08 | 2022-03-09 | Université d'Aix-Marseille | Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues |
| JP2024513260A (ja) | 2021-04-08 | 2024-03-22 | オリゾン ジェノミックス ソシエダッド アノニマ | 骨髄癌処置のためのｌｓｄ１阻害剤の組み合わせ |
| JP2025516648A (ja) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法 |
| CN119546292A (zh) | 2022-05-09 | 2025-02-28 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗恶性周围神经鞘瘤(mpnst)的方法 |
| CN116077661B (zh) * | 2022-08-22 | 2024-09-27 | 沈阳药科大学 | Kdm1a抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途 |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040110963A1 (en) * | 2001-01-22 | 2004-06-10 | Kaspar Burri | Novel hydrazones |
| JP2002302472A (ja) * | 2001-01-31 | 2002-10-18 | Meiji Seika Kaisha Ltd | メイラード反応阻害剤 |
| RU2006104697A (ru) | 2003-07-16 | 2006-06-27 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. (Jp) | Лекарственное средство для лечения пигментации кожи |
| WO2006136008A1 (en) | 2005-05-24 | 2006-12-28 | University Health Network | Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer |
| TW200800145A (en) * | 2005-08-26 | 2008-01-01 | Dekk Tec Inc | Hydrazone agents to treat cutaneous lesions |
| US20070207093A1 (en) | 2005-11-03 | 2007-09-06 | Linquagen Corp. | Hydrazone derivatives and uses thereof |
| US8338464B2 (en) | 2006-11-30 | 2012-12-25 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of BCL6 |
| JP2010518008A (ja) | 2007-02-02 | 2010-05-27 | レッドポイント バイオ コーポレイション | インスリンおよびｇｌｐ−１の放出を調節するｔｒｐｍ５阻害物質 |
| EP2142498A2 (en) * | 2007-04-02 | 2010-01-13 | Institute for Oneworld Health | Cftr inhibitor compounds and uses thereof |
| WO2009027349A2 (en) * | 2007-08-24 | 2009-03-05 | Oryzon Genomics Sa | Treatment and prevention of neurodegenerative diseases |
| AR070898A1 (es) * | 2008-03-18 | 2010-05-12 | Solvay Pharm Bv | Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6 |
| WO2010003023A2 (en) | 2008-07-01 | 2010-01-07 | Zacharon Pharmaceuticals, Inc. | Heparan sulfate inhibitors |
| EP2376435A2 (en) * | 2009-01-14 | 2011-10-19 | Dow AgroSciences LLC | Synergistic fungicidal compositions including hydrazone derivatives and copper |
| CA2727890A1 (en) * | 2010-01-13 | 2011-07-13 | Norbert Kartner | Compounds, compositions and treatments for v-atpase related diseases |
-
2012
- 2012-08-15 JP JP2014526170A patent/JP6122006B2/ja active Active
- 2012-08-15 SM SM20200551T patent/SMT202000551T1/it unknown
- 2012-08-15 WO PCT/US2012/050948 patent/WO2013025805A1/en not_active Ceased
- 2012-08-15 HU HUE12823540A patent/HUE050962T2/hu unknown
- 2012-08-15 BR BR112014003382-0A patent/BR112014003382B1/pt active IP Right Grant
- 2012-08-15 ES ES12823540T patent/ES2821548T3/es active Active
- 2012-08-15 MX MX2014001842A patent/MX356486B/es active IP Right Grant
- 2012-08-15 CN CN201280050736.9A patent/CN103929960B/zh active Active
- 2012-08-15 DK DK12823540.5T patent/DK2744330T3/da active
- 2012-08-15 EA EA201490453A patent/EA026389B1/ru unknown
- 2012-08-15 HK HK15100490.8A patent/HK1200052A1/xx unknown
- 2012-08-15 SG SG2014009609A patent/SG2014009609A/en unknown
- 2012-08-15 CA CA2843609A patent/CA2843609C/en active Active
- 2012-08-15 US US13/586,603 patent/US8987335B2/en active Active
- 2012-08-15 LT LTEP12823540.5T patent/LT2744330T/lt unknown
- 2012-08-15 PT PT128235405T patent/PT2744330T/pt unknown
- 2012-08-15 IN IN961CHN2014 patent/IN2014CN00961A/en unknown
- 2012-08-15 EP EP12823540.5A patent/EP2744330B1/en active Active
- 2012-08-15 HR HRP20201433TT patent/HRP20201433T1/hr unknown
- 2012-08-15 AU AU2012296639A patent/AU2012296639B2/en active Active
- 2012-08-15 KR KR1020147006969A patent/KR101983537B1/ko active Active
- 2012-08-15 SI SI201231841T patent/SI2744330T1/sl unknown
- 2012-08-15 PL PL12823540T patent/PL2744330T3/pl unknown
-
2014
- 2014-01-30 IL IL230728A patent/IL230728A/en active IP Right Grant
- 2014-02-05 ZA ZA2014/00881A patent/ZA201400881B/en unknown
-
2015
- 2015-02-16 US US14/623,370 patent/US9555024B2/en not_active Expired - Fee Related
-
2020
- 2020-09-14 CY CY20201100866T patent/CY1123345T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201433T1 (hr) | Supstituirani (e)-n´- (1-feniletiliden) analozi benzohidrazida kao inhibitori histonske demetilaze | |
| EA201490535A1 (ru) | Пирролбензодиазепины | |
| EA201591000A1 (ru) | Пирролобензодиазепины | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| JP2016523256A5 (https=) | ||
| AR086958A1 (es) | Antagonistas de trpv4 | |
| NZ627036A (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| RU2013116924A (ru) | N1/n2-лактамные ингибиторы ацетил-коа-карбоксилаз | |
| AR093123A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| CO6150161A2 (es) | Ciclopenta [d] pirimidinas hidroxiladas y metoxiladas como inhibidores de la proteina kinasa akt | |
| MY155133A (en) | Compounds having crth2 antagonist activity | |
| EA201070235A1 (ru) | Новые производные 6-триазолпиридинсульфанил-бензотиазола и -бензимидазола, способ их получения, применение их в качестве лекарственных средств, фармацевтические композиции и новое применение, а именно в качестве ингибиторов met | |
| IN2014MN02175A (https=) | ||
| WO2015001457A3 (en) | Compositions with improved urease-inhibiting effect comprising (thio)phosphoric acid triamide and further compounds | |
| MX2009003802A (es) | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta-2 adrenergico. | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| HRP20192144T1 (hr) | Heterociklični inhibitori glutaminaze | |
| AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| MX344276B (es) | Compuesto de piperidina novedoso o sal del mismo. | |
| HRP20191482T1 (hr) | 18f-označeni psma ciljani pet reagensi | |
| JO3509B1 (ar) | معدلات p2x7 | |
| MX2013013041A (es) | Nuevos compuestos y composiciones para la inhibicion de nampt. | |
| MY159870A (en) | Piperazine compound capable of inhibiting prostaglandin d synthase | |
| MX2020014087A (es) | Moléculas inmunomoduladoras pequeñas novedosas. | |
| AR068658A1 (es) | Derivados de tiazol |